Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05148871 Active, not recruiting - COVID-19 Clinical Trials

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Start date: March 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)

NCT ID: NCT05148858 Not yet recruiting - COVID-19 Clinical Trials

Sleep Quality and Quality of Life in Coronavirus 19 Disease ( COVID 19) Patients

Start date: April 1, 2022
Phase:
Study type: Observational

To study the impact of COVID 19 infection on sleep habit as regards quality of sleep, emergence of insomnia. To assess quality of life in patients after COVID 19 infection.

NCT ID: NCT05148845 Recruiting - Clinical trials for SARS CoV 2 Infection

Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Sisonke Boost
Start date: November 10, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and unvaccinated populations in South Africa

NCT ID: NCT05148832 Completed - COVID-19 Clinical Trials

Administration of Systemic Corticosteroids and the Recovery of Gustatory Functions in Patients With COVID-19

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Coronavirus is a global pandemic with a high mortality rate; it is started in china in 2019 and rapidly spread worldwide, reaching its epidemic peak in March 2020 Coronavirus is a family of viruses that usually affect animals. They also can affect the respiratory system of humans, causing different manifestations such as difficulty in breathing, coughing, fever, invasive lung lesions, and viral pneumonia

NCT ID: NCT05148819 Not yet recruiting - COVID-19 Clinical Trials

Assessment of Sexual Dysfunction Among COVID-19 Recovered Patients

Start date: January 1, 2022
Phase:
Study type: Observational

Covid-19 pandemic has affected hundreds of millions globally(https ://coronavirus.jhu.edu/map.html), and hundreds of thousands in Egypt(https://www.care.gov.eg/EgyptCare/Index.aspx). However, the long-term consequences of the disease are still largely unknown. Data from 2002-2004 epidemics of SARS suggest that cardiovascular sequelae, such as microangiopathy, cardiomyopathy and impaired endothelial function, are to be expected also in COVID-19 patients.(Vittori et al, 2020) Hyperinflammation and immunosuppression are prominently featured in COVID-19, causing a cytokine storm leading to development of micro-thrombosisand disseminated intravascular coagulation (DIC). (Jose et al, 2020). These findings can be extremely relevant for male and female sexual health: indeed, based on these premises, there is quite enough evidence to hypothesize that consequences of COVID-19 can extend to sexual and reproductive health. (Sansone et al, 2020) A self-administered questionnaire will be disseminated using online electronic social network (Facebook, What's App) including: Sociodemographic age& gender. Sexual dysfunction will be assessed using International Index of Erectile Function-5 (IIEF-5) for males, and Arabic Female Sexual Function Index (ArFSFI) for females will be applied. Covid-19 related factors.

NCT ID: NCT05148754 Completed - Covid19 Clinical Trials

An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers

Start date: January 23, 2021
Phase: Phase 1
Study type: Interventional

An open-label clinical study of the pharmacokinetics and safety of Elsulfavirine, 200 mg tablets, with single and multiple oral administration in healthy volunteers.

NCT ID: NCT05148676 Completed - COVID-19 Pandemic Clinical Trials

Residual Symptoms and the Quality of Life in Individuals Recovered From COVID-19 Infection: A Survey From Pakistan

Start date: November 1, 2020
Phase:
Study type: Observational

There remains scarcity of literature regarding the patient's health status post-COVID-19 infection. This study analyzes the prevalence of residual symptoms and quality of life (QoL) after COVID-19.

NCT ID: NCT05148091 Completed - COVID-19 Clinical Trials

The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by Sinocelltech, Ltd. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental vaccine in healthy adults aged ≥ 18 Years previously unvaccinated.

NCT ID: NCT05145803 Recruiting - COVID-19 Clinical Trials

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

Start date: March 15, 2021
Phase:
Study type: Observational

The overall aim of this study is to measure how transmission of COVID-19 occurs in communities - including the role of super spreaders and/or identifying conditions that may increase transmission risk, with a focus on congregant situations. In order to identify how presence of symptoms and behavior affects the transmissibility of the virus, the investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using polyvinyl alcohol (PVA) test strips embedded in face masks (Face Mask Sampling- "FMS") - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air.

NCT ID: NCT05145751 Completed - COVID-19 Clinical Trials

SARS CoV-2 Infection and Inflammatory Biomarkers

Start date: April 1, 2021
Phase:
Study type: Observational

Early research suggests that inflammation plays a key role in the development of SARS CoV-2 infection. The immune response to respiratory infection is characterized by an influx of neutrophils to the lungs. This study ought to investigate the association of simple biomarkers such as NLR and PLR with the clinical outcome in SARS CoV-2 infection patients.